EFFECT OF ROSUVASTATIN ON CAROTID INTIMAMEDIA THICKNESS IN PATIENTS WITH CORONARY ARTERY DISEASE OF DIFFERENT GENDER AND CARDIOVASCULAR RISK PROFILE


Cite item

Full Text

Abstract

Secondary prevention in patients with coronary artery disease (CAD) is provided by the use of statins, as well as by the impact on modiable risk factors. Rosuvastatin causes the regression of intima-media thickness (IMT) of common carotid artery (CCA), which is signicantly associated with CAD. The aim of the study was to evaluate the change in carotid intima-media thickness (CIMT) in patients with CAD of different gender, and having different number of cardiovascular risk factors, provided that patients attain target levels of total cholesterol (TC<4.0 mmol/l) and low density lipoprotein-cholesterol (LDL-C><1.8 mmol/l). Materials and methods. 72 patients with CAD: Stable angina of functional Classes II–III were recruited. They were treated with rosuvastatin, with gradual increase of its dose from 5 to 40 mg daily to attain target levels of TC and LDL-C. Maximum CIMT was assessed at the time of inclusion into the study and after 12 months of therapy. Results and discussion. In conditions of attaining target TC and LDL-C levels, maximum CIMT signi cantly decreased both in men (p=0,006) and in women (p=0,002), the latter had lower CIMT (p=0,03) than men after 1 year of therapy, taking into account no difference in baseline values. The patients who had 2 or fewer risk factors (RF) (hypertension, a family history of cardiovascular disease, smoking, obesity, diabetes mellitus were taken into consideration) showed decrease in CIMT (p=0.0001), and those who were characterized by 3 or more RF, showed only lack of its growth (p=0.07). Attained lipid levels in the compared groups of different gender and number of RF did not differ. Conclusion. The study revealed the differences in the change of CIMT in patients with CAD of different sex, and of different number of cardiovascular risk factors. Keywords: coronary artery disease, rosuvastatin, carotid intima-media thickness, gender, cardiovascular risk factor ><4.0 mmol/l) and low density lipoprotein-cholesterol (LDL-C<1.8 mmol/l). Materials and methods. 72 patients with CAD: Stable angina of functional Classes II–III were recruited. They were treated with rosuvastatin, with gradual increase of its dose from 5 to 40 mg daily to attain target levels of TC and LDL-C. Maximum CIMT was assessed at the time of inclusion into the study and after 12 months of therapy. Results and discussion. In conditions of attaining target TC and LDL-C levels, maximum CIMT signicantly decreased both in men (p=0,006) and in women (p=0,002), the latter had lower CIMT (p=0,03) than men after 1 year of therapy, taking into account no difference in baseline values. The patients who had 2 or fewer risk factors (RF) (hypertension, a family history of cardiovascular disease, smoking, obesity, diabetes mellitus were taken into consideration) showed decrease in CIMT (p=0.0001), and those who were characterized by 3 or more RF, showed only lack of its growth (p=0.07). Attained lipid levels in the compared groups of different gender and number of RF did not differ. Conclusion. The study revealed the differences in the change of CIMT in patients with CAD of different sex, and of different number of cardiovascular risk factors.

About the authors

S. I. Kononov

Federal State Budgetary Educational Organization of Higher Education “Kursk State Medical University” of Ministry of Health of Russian Federation

Email: ck325@yandex.ru

G. S. Mal

Federal State Budgetary Educational Organization of Higher Education “Kursk State Medical University” of Ministry of Health of Russian Federation

Email: mgalina.2013@mail.ru

References

  1. Karlson B.W., Palmer M.K., Nicholls S.J., Barter P.J., Lundman P. Effects of age, gender and statin dose on lipid levels: Results from the VOYAGER meta-analysis database. Atherosclerosis. 2017. Vol. 265. P. 54–59. doi: 10.1016/j.atherosclerosis.2017.08.014
  2. Арутюнов А.Г., Арутюнов Г.П. Коррекция статинами сердечно-сосудистого риска. Проблемы и нерешенные вопросы на современном этапе // Сердце: журнал для практикующих врачей. 2015. Т. 14. №4. С. 193–212. doi: 10.18087/rhj.2015.4.2093
  3. Greenland P., Alpert J.S., Beller G.A., Benjamin E.J., Budoff M.J., Fayad Z.A., Foster E., Hlatky M.A., Hodgson J., Kushner F.G., Lauer M.S., Shaw L.J., Smith S.C., Taylor A.J., Weintraub W.S., Wenger N.K. 2010 ACCF/ AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2010. No. 56 (25). P. e50–103. doi: 10.1016/j.jacc.2010.09.001
  4. Российское кардиологическое общество. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации. V пересмотр // Российский кардиологический журнал. 2012. Т. 4. №96. Прил. 1.
  5. Łoboz-Rudnicka M., Jaroch J., Bociąga Z., Rzyczkowska B., Uchmanowicz I., Polański J., Dudek K., Szuba A., Łoboz-Grudzień K. Impact of cardiovascular risk factors on carotid intima-media thickness: sex differences. Clin Interv Aging. 2016. No. 11. P. 721-31. doi: 10.2147/CIA.S103521
  6. Li X., Liu M., Sun R., Zeng Y., Chen S., Zhang P. Atherosclerotic coronary artery disease: The accuracy of measures to diagnose preclinical atherosclerosis. Exp. Ther. Med. 2016. No. 12 (5). P. 2899–2902. DOI: 10.3892/ etm.2016.3710
  7. Baroncini L.A.V, de Castro Sylvestre L., Filho R.P. Carotid intima-media thickness and carotid plaque represent different adaptive responses to traditional cardiovascular risk factors. Int J Cardiol Heart Vasc. 2015. No. 9. P. 48-51. doi: 10.1016/j.ijcha.2015.08.003
  8. Jones P.H., Davidson M.H., Stein E.A., Bays H.E., McKenney J.M., Miller E. Comparison of the Ef cacy and Safety of Rosuvastatin Versus Atorvastatin, Simvastatin, and Pravastatin Across Doses (STELLAR* Trial). Am. J. Cardiol. 2003. No. 92 (2). P. 152–160.
  9. Драпкина О.М., Чернова Е.М. Миопатия как побочный эффект терапии статинами: механизмы развития и перспективы лечения // Рациональная фармакотерапия в кардиологии. 2015. №11 (1). C. 96–101.
  10. Kjekshus J., Dunselman P., Blideskog M., Eskilson C., Hjalmarson A., McMurray J.V., Waagstein F., Wedel H., Wessman P., Wikstrand J.; CORONA Study Group. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail. 2005. No. 7(6). P. 1059–1069.
  11. Kjekshus J., Apetrei E., Barrios V., Böhm M., Cleland J.G., Cornel J.H., Dunselman P., Fonseca C., Goudev A., Grande P., Gullestad L., Hjalmarson A., Hradec J., Jánosi A., Kamenský G., Komajda M., Korewicki J., Kuusi T., Mach F., Mareev V., McMurray J.J., Ranjith N., Schaufelberger M., Vanhaecke J., van Veldhuisen D.J., Waagstein F., Wedel H., Wikstrand J.; CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007. No. 357. P. 2248–2261. doi: 10.1056/NEJMoa0706201
  12. Crouse J.R. 3rd, Raichlen J.S., Riley W.A., Evans G.W., Palmer M.K., O’Leary D.H., Grobbee D.E., Bots M.L.; METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA. 2007. No. 297 (12). P. 1344–1353. doi: 10.1001/jama.297.12.1344
  13. Ballantyne C.M., Raichlen J.S., Cain V.A., Nicholls S.J., Nissen S.E., Erbel R., Tardif J.-C., Brener S.J.; ASTEROID Investigators. Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Circulation. 2008. No. 117. P. 2458–2466. doi: 10.1161/CIRCULATIONAHA.108.773747
  14. Puri R., Libby P., Nissen S.E., Wolski K., Ballantyne C.M., Barter P.J., Chapman M.J., Erbel R., Raichlen J.S., Uno K., Kataoka Y., Tuzcu E.M., Nicholls S.J. Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN. Eur Heart J Cardiovasc Imaging. 2014. No. 15(4). P. 380–388. doi: 10.1093/ehjci/jet251
  15. Puri R., Nissen S.E., Shao M., Ballantyne C.M., Barter P.J., Chapman M.J., Erbel R., Libby P., Raichlen J.S., Uno K., Kataoka Y., Nicholls S.J. Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy: insights from SATURN. JACC Cardiovasc Imaging. 2014. No. 7(10). P. 1013–22. doi: 10.1016/j.jcmg.2014.04.019
  16. Kataoka Y., Puri R., Hammadah M., Duggal B., Uno K., Kapadia S.R., Tuzcu E.M., Nissen S.E., King P., Nicholls S.J. Sex Differences in Nonculprit Coronary Plaque Microstructures on Frequency-Domain Optical Coherence Tomography in Acute Coronary Syndromes and Stable Coronary Artery Disease. Circ Cardiovasc Imaging. 2016. No. 9(8). P. e004506. doi: 10.1161/CIRCIMAGING.116.004506
  17. Persson L., Henriksson P., Westerlund E., Hovatta O., Angelin B., Rudling M. Endogenous estrogens lower plasma PCSK9 and LDL cholesterol but not Lp (a) or bile acid synthesis in women. Arterioscler. Thromb. Vasc. Biol. 2012. No. 32 (3). P. 810–814.
  18. Reckless J. Addressing residual cardiovascular risk: what does the future hold? Br J Cardiol. 2012. No. 19 (1). P. 1–16.
  19. Балахонова Т.В., Трипотень М.И., Погорелова О.А. Ультразвуковые методы оценки толщины комплекса интима-медиа артериальной стенки // SonoAce-Ultrasound. 2010. № 21. С. 57–63.
  20. Ультразвуковая диагностика сосудистых заболеваний / под ред. В.П. Куликова. М.: ООО Фирма «Стром», 2007. 512 c.: ил.
  21. Ten Haaf M.E., Rijndertse M., Cheng J.M., de Boer S.P., Garcia-Garcia H.M., van Geuns R.M., Regar E., Lenzen M.J., Appelman Y., Boersma E. Sex differences in plaque characteristics by intravascular imaging in patients with coronary artery disease. EuroIntervention. 2017. No. 13(3). P. 320–328. doi: 10.4244/EIJ-D-16-00361
  22. Tabatabaei-Malazy O., Fakhrzadeh H., Shari F., Miraren M., Badamchizadeh Z., Larijani B. Gender differences in association between metabolic syndrome and carotid intima media thickness. J Diabetes Metab Disord. 2012. No. 11 (1). P. 13. doi: 10.1186/2251-6581-11-13
  23. Карпов Ю.А., Сорокин Е.В. Факторы риска ИБС: когда и как проводить коррекцию? Повышение роли статинов // Русский Медицинский Журнал. 2003. № 19. С. 1041–1045.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Kononov S.I., Mal G.S.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС 77 - 67428 от 13.10.2016. 

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies